Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aMMbition: Cilta-cel, Tal-D, and Tec-D in Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Sep 2030
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 5
01
Overview
A Phase 2 trial of ciltacabtagene autoleucel, talquetamab, teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Aug 2024; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleuceltalquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06577025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577025.